Voraxaze out-licensed in Japan

UK health care firm BTG (LSE: BGC) says that it has licensed the Japanese rights to glucarpidase (which carries the trade name Voraxaze) to Japan’s Ohara Pharmaceutical. Under the terms of the license agreement BTG will also supply glucarpidase to Ohara.

Ohara will be responsible for the development program and registration in Japan. The Japanese firm plans to work in partnership with leading oncologists who will execute clinical trials in a development program for glucarpidase. This is a clinical trial project funded by a Health and Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare (MHLW). An IND application for glucarpidase in Japan was submitted to the Pharmaceuticals and Medical Devices Agency on December 5. Should glucarpidase be successfully developed and approved, Ohara will have the rights to market and sell glucarpidase in Japan.

Ohara developing orphan drug business in Japan